Sunday, April 12, 2015 6:16:58 PM
Major Research Presented and Published at the Critical Care Congress in Phoenix, Arizona, Utilizing the Daxor BVA-100 Blood Volume Analyzer
NEW YORK, NY--(Marketwired - Jan 30, 2015) - Daxor Corporation (NYSE MKT: DXR) -- A study on 50 patients with severe sepsis published in the journal Critical Care Medicine, Volume 42, No. 12, December 2014, entitled Central Venous Pressure: Is It An Accurate Reflection of Intravascular Volume Status? analyzed whether central venous pressure is an accurate reflection of intravascular blood volume status. The authors of the study from the University of Hawaii, Drs. Catherine Lindsay McKnight, Mihae Yu, et al., utilizing the BVA-100 blood volume analyzer, found 17% of the patients who developed a normal or high central venous pressure can still be hypovolemic (low blood volume) and, therefore, would be under treated utilizing this common procedure.
Central venous pressure is a commonly used semi-invasive procedure to treat septic patients in intensive care units. Septic patients commonly have death rates ranging between 20 to 40% because of the collapse of their circulation. Correct volume replacement is essential to avoid inadequate treatment as well as to avoid over treatment with saline which may flood the lungs with sterile salt water. Direct blood volume measurement with the BVA-100 blood volume analyzer avoids these complications.
Another study titled Persistently High albumin Leak is Associated With Mortality by Scott Harvey, Mihae Yu, et al., also appearing in the journal Critical Care Medicine, and also involving 50 people, demonstrated that patients with a high albumin leak have an increased mortality rate. Significantly higher death rates were observed in patients on days 3 to 5 of their admission to the intensive care unit. The BVA-100 was utilized in this study also.
Dr. Mihae Yu, senior author of these studies has previously published a landmark study in the journal Shock in 2011. This prospective study of 100 patients with sepsis compared patients treated with blood volume measurements vs. patients treated without this data, there was a 24% death rate with patients treated with standard procedures such as pulmonary artery catheterization (PAC) vs. an 8% death rate in patients treated utilizing blood volume measurement for goal directed therapy. This was a remarkable difference in the treatment of sepsis, which has not only a high death rate, but significant morbidity such as permanent brain damage in patients who survive their time in the intensive care unit.
Daxor Corporation manufactures and markets the only FDA approved Blood Volume Analyzer, the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's BVA-100 Blood Volume Analyzer, visit Daxor's website at www.Daxor.com.
http://finance.yahoo.com/news/daxor-corporation-announces-major-research-133000398.html
Recent DXR News
- Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management • GlobeNewswire Inc. • 09/12/2024 12:00:00 PM
- Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care • GlobeNewswire Inc. • 09/04/2024 12:30:00 PM
- Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter • GlobeNewswire Inc. • 09/03/2024 08:05:00 PM
- Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 04:15:00 PM
- Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public) • Edgar (US Regulatory) • 08/29/2024 09:27:54 PM
- Form N-CSRS - Certified Shareholder Report, Semi-Annual • Edgar (US Regulatory) • 08/29/2024 09:16:22 PM
- Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network • GlobeNewswire Inc. • 08/29/2024 12:00:00 PM
- Form 40-17G - Fidelity Bond [Rule 17G-1(g)] • Edgar (US Regulatory) • 08/23/2024 08:52:16 PM
- Form N-2 - Registration statement for closed-end investment companies • Edgar (US Regulatory) • 08/16/2024 09:23:21 PM
- Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer • GlobeNewswire Inc. • 08/06/2024 12:00:00 PM
- Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer • GlobeNewswire Inc. • 07/24/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 06:46:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 10:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:54:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:50:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 09:46:48 PM
- Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide • GlobeNewswire Inc. • 07/11/2024 12:00:00 PM
- Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:10:05 PM
- Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™) • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM